Skip to main content
SpringerLink
Log in

Noncorticosteroid Intraocular Drug Therapy

  • Chapter
Surgical Management of Inflammatory Eye Disease

  • 840 Accesses

Abstract

■ The use of noncorticosteroid anti-inflammatory agents opens a wide range of possibilities to regulating specific pathways involved in immune reactions, cytokine production or cell death.

■ In order to achieve this specificity, drug delivery to the target tissue or cell is part of an efficient and safe ocular therapy. Particularly, for the treatment of recurrent intraocular inflammation, local and sustained delivery of the therapeutic agent is required to limit systemic side effects and reduce the need for repeated intraocular administration.

■ Among the different strategies proposed, attention must be paid to minimize iatrogenic inflammation that might be caused by the material or the procedure used to deliver the therapeutic compounds.

■ Most of the described technologies are still at the bench state, but they represent new and exciting potential for future clinical applications.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Smith TJ, Pearson PA, Blandford DL, Brown JD, Goins KA, Hollins JL, Schmeisser ET, Glavinos P, Baldwin LB and Ashton P. Intravitreal sustained-release ganciclovir, Arch Ophthalmol 110 (1992), pp. 255–8

    PubMed  CAS  Google Scholar 

  2. Lim JI, Wolitz RA, Dowling AH, Bloom HR, Irvine AR and Schwartz DM. Visual and anatomic outcomes associated with posterior segment complications after ganciclovir implant procedures in patients with AIDS and cytomegalovirus retinitis, Am J Ophthalmol 127 (1999), pp. 288–93

    Article  PubMed  CAS  Google Scholar 

  3. Driot JY, Novack GD, Rittenhouse KD, Milazzo C and Pearson PA. Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period, J Ocul Pharmacol Ther 20 (2004), pp. 269–75

    Article  PubMed  CAS  Google Scholar 

  4. Yasukawa T, Ogura Y, Sakurai E, Tabata Y and Kimura H. Intraocular sustained drug delivery using implantable polymeric devices, Adv Drug Deliv Rev 57 (2005), pp. 2033–46

    Article  PubMed  CAS  Google Scholar 

  5. Merkli A, Tabatabay C, Gurny R and Heller J. Biodegradable polymers for the controlled release of ocular drugs, Prog Polym Sci 23 (1998), pp. 563–580

    Article  CAS  Google Scholar 

  6. Einmahl S, Ponsart S, Bejjani RA, D’Hermies F, Savoldelli M, Heller J, Tabatabay C, Gurny R and Behar-Cohen F. Ocular biocompatibility of a poly(ortho ester) characterized by autocatalyzed degradation, J Biomed Mater Res A 67 (2003), pp. 44–53

    Article  PubMed  Google Scholar 

  7. Mainardes RM and Silva LP. Drug delivery systems: past, present, and future, Curr Drug Targets 5 (2004), pp. 449–55

    Article  PubMed  CAS  Google Scholar 

  8. Mainardes RM, Urban MC, Cinto PO, Khalil NM, Chaud MV, Evangelista RC and Gremiao MP. Colloidal carriers for ophthalmic drug delivery, Curr Drug Targets 6 (2005), pp. 363–71

    Article  PubMed  CAS  Google Scholar 

  9. Khoobehi B, Stradtmann MO, Peyman GA and Aly OM. Clearance of sodium fluorescein incorporated into microspheres from the vitreous after intravitreal injection, Ophthalmic Surg 22 (1991), pp. 175–80

    PubMed  CAS  Google Scholar 

  10. Sakurai E, Ozeki H, Kunou N and Ogura Y. Effect of particle size of polymeric nanospheres on intravitreal kinetics, Ophthalmic Res 33 (2001), pp. 31–6

    Article  PubMed  CAS  Google Scholar 

  11. Bourges JL, Gautier SE, Delie F, Bejjani RA, Jeanny JC, Gurny R, BenEzra D and Behar-Cohen FF. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles, Invest Ophthalmol Vis Sci 44 (2003), pp. 3562–9

    Article  PubMed  Google Scholar 

  12. Ebrahim S, Peyman GA and Lee PJ. Applications of liposomes in ophthalmology, Surv Ophthalmol 50 (2005), pp. 167–82

    Article  PubMed  Google Scholar 

  13. Bochot A, Fattal E, Boutet V, Deverre JR, Jeanny JC, Chacun H and Couvreur P. Intravitreal delivery of oligonucleotides by sterically stabilized liposomes, Invest Ophthalmol Vis Sci 43 (2002), pp. 253–9

    PubMed  Google Scholar 

  14. Bloquel C, Bejjani R, Bigey P, Bedioui F, Doat M, BenEzra D, Scherman D and Behar-Cohen F. Plasmid electrotransfer of eye ciliary muscle: principles and therapeutic efficacy using hTNF-alpha soluble receptor in uveitis, FASEB J 20 (2006), pp. 389–91

    PubMed  CAS  Google Scholar 

  15. Nishi O, Nishi K, Morita T, Tada Y, Shirasawa E and Sakanishi K. Effect of intraocular sustained release of indomethacin on postoperative inflammation and posterior capsule opacification, J Cataract Refract Surg 22 (1996), pp. 806–10

    PubMed  Google Scholar 

  16. Ayalasomayajula SP and Kompella UB. Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model, Eur J Pharmacol 511 (2005), pp. 191–8

    Article  PubMed  CAS  Google Scholar 

  17. Blandford DL, Smith TJ, Brown JD, Pearson PA and Ashton P. Subconjunctival sustained release 5-fluorouracil, Invest Ophthalmol Vis Sci 33 (1992), pp. 3430–5

    PubMed  CAS  Google Scholar 

  18. Smith TJ and Ashton P. Sustained-release subconjunctival 5-fluorouracil, Ophthalmic Surg Lasers 27 (1996), pp. 763–7

    PubMed  CAS  Google Scholar 

  19. Wang G, Tucker IG, Roberts MS and Hirst LW. In vitro and in vivo evaluation in rabbits of a controlled release 5-fluorouracil subconjunctival implant based on poly(D,L-lactide-co-glycolide), Pharm Res 13 (1996), pp. 1059–64

    Article  PubMed  CAS  Google Scholar 

  20. Jampel HD, Thibault D, Leong KW, Uppal P and Quigley HA. Glaucoma filtration surgery in nonhuman primates using taxol and etoposide in polyanhydride carriers, Invest Ophthalmol Vis Sci 34 (1993), pp. 3076–83

    PubMed  CAS  Google Scholar 

  21. Einmahl S, Behar-Cohen F, D’Hermies F, Rudaz S, Tabatabay C, Renard G, et al. A new poly(ortho ester)-based drug delivery system as an adjunct treatment in filtering surgery, Invest Ophthalmol Vis Sci 42 (2001), pp. 695–700

    PubMed  CAS  Google Scholar 

  22. Pandey SK, Cochener B, Apple DJ, Colin J, Werner L, Bougaran R, et al. Intracapsular ring sustained 5-fluorouracil delivery system for the prevention of posterior capsule opacification in rabbits: a histological study, J Cataract Refract Surg 28 (2002), pp. 139–48

    Article  PubMed  Google Scholar 

  23. Yasukawa T, Ogura Y, Sakurai E, Tabata Y and Kimura H. Intraocular sustained drug delivery using implantable polymeric devices, Adv Drug Deliv Rev 57 (2005), pp. 2033–46

    Article  PubMed  CAS  Google Scholar 

  24. Sun JK and Arroyo JG. Adjunctive therapies for proliferative vitreoretinopathy, Int Ophthalmol Clin 44(3) (2004), pp. 1–10

    Article  PubMed  Google Scholar 

  25. Pearson PA, Jaffe GJ, Martin DF, Cordahi GJ, Grossniklaus H, Schmeisser ET, et al. Evaluation of a delivery system providing long-term release of cyclosporine, Arch Ophthalmol 114 (1996), pp. 311–7

    PubMed  CAS  Google Scholar 

  26. Beeley NR, Stewart JM, Tano R, Lawin LR, Chappa RA, Qiu G, Anderson AB, de Juan E and Varner SE. Development, implantation, in vivo elution, and retrieval of a biocompatible, sustained release subretinal drug delivery system, J Biomed Mater Res A 76 (2006), pp. 690–8

    PubMed  Google Scholar 

  27. de Kozak Y, Andrieux K, Villarroya H, Klein C, Thillaye-Goldenberg B, Naud MC, et al. Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis, Eur J Immunol 34 (2004), pp. 3702–12

    Article  PubMed  Google Scholar 

  28. Anand R, Nightingale SD, Fish RH, Smith TJ and Ashton P. Control of cytomegalovirus retinitis using sustained release of intraocular ganciclovir, Arch Ophthalmol 111 (1993), pp. 223–7

    PubMed  CAS  Google Scholar 

  29. Martin DF, Parks DJ, Mellow SD, Ferris FL, Walton RC, Remaley NA, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant: a randomized controlled clinical trial, Arch Ophthalmol 112 (1994), pp. 1531–9

    PubMed  CAS  Google Scholar 

  30. Martin DF, Dunn JP, Davis JL, Duker JS, Engstrom RE Jr, Friedberg DN, Jaffe GJ, Kuppermann BD, Polis MA, Whitley RJ, Wolitz RA and Benson CA. Use of the ganciclovir implant for the treatment of cytomegalovirus retinitis in the era of potent antiretroviral therapy: recommendations of the International AIDS Society-USA panel, Am J Ophthalmol 127 (1999), pp. 329–39

    Article  PubMed  CAS  Google Scholar 

  31. Yasukawa T, Kimura H, Kunou N, Miyamoto H, Honda Y, Ogura Y and Ikada Y. Biodegradable scleral implant for intravitreal controlled release of ganciclovir, Graefes Arch Clin Exp Ophthalmol 238 (2000), pp. 186–90

    Article  PubMed  CAS  Google Scholar 

  32. Veloso AA Jr, Zhu Q, Herrero-Vanrell R and Refojo MF. Ganciclovir-loaded polymer microspheres in rabbit eyes inoculated with human cytomegalovirus, Invest Ophthalmol Vis Sci 38 (1997), pp. 665–75

    PubMed  Google Scholar 

  33. Yamakawa I, Ishida M, Kato T, Ando H and Asakawa N. Release behavior of poly(lactic acid-co-glycolic acid) implants containing phosphorothioate oligodeoxynucleotide, Biol Pharm Bull 20 (1997), pp. 455–9

    PubMed  CAS  Google Scholar 

  34. Gomes dos Santos AL, Bochot A, Tsapis N, Artzner F, Bejjani RA, Thillaye-Goldenberg B and Behar-Cohen F. Oligonucleotide-polyethylenimine complexes targeting retinal cells: structural analysis and application to anti-TGFbeta-2 therapy, Pharm Res 23 (2006), pp. 770–81

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, INSERM, 15 rue de l’Ecole de Médecine, 74006, Paris, France

    Francine Behar-Cohen & Jean-Louis Bourges

Authors
  1. Francine Behar-Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jean-Louis Bourges
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Universitäts-Augenklinik Heidelberg, Interdisziplinäres Uveitiszentrum, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany

    Matthias Becker

  2. Dept. of Ophthalmology, Triemli Hospital Zürich, Birmensdorfer Straße 497, 8063, Zürich, Switzerland

    Matthias Becker

  3. Ophthalmology, Univ. of Miami Bascom Palmer, 900 NW 17th Street, 33136, Miami, FL, FL, USA

    Janet Davis

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Behar-Cohen, F., Bourges, JL. (2008). Noncorticosteroid Intraocular Drug Therapy. In: Becker, M., Davis, J. (eds) Surgical Management of Inflammatory Eye Disease. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-33862-8_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-33862-8_3

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-33861-1

  • Online ISBN: 978-3-540-33862-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation